Evidence of mitochondrial and lysosome dysfunction underlying Parkinson’s disease (PD) was discussed during several talks at the World Parkinson Congress 2023 (WPC) held in Barcelona. Edward A. Fon, from McGill University in Montreal, explained how eyes turned to mitochondria as key players in PD more than 30 years ago and how the explosion of genetics was fundamental to advance the knowledge and research in PD.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified monoglyceride lipase (MGLL; MAGL) inhibitors reported to be useful for the treatment of neuroinflammation, neurodegeneration, pain, cancer, diarrhea, inflammatory bowel disease, irritable bowel syndrome and psychiatric disorders.
The U.S. Department of Health and Human Services has synthesized cannabinoid CB1 receptor antagonists reported to be useful for the treatment of cancer, metabolic, psychiatric, neurological, pain, gastrointestinal, inflammation, and substance abuse and dependence.
Spinogenix Inc. is opening enrollment in a first-in-human phase I trial of SPG-302 for the treatment of amyotrophic lateral sclerosis (ALS), having received approval from Australia's Human Research Ethics Committee (HREC).
The loss of the dopaminergic neurons in the substantia nigra and their projections in the putamen cause motor disabilities, which are one of the main hallmarks in patients with Parkinson’s disease (PD).
Cannabidiol derivatives potentially useful for the treatment of Parkinson’s disease and epilepsy have been described in a Deyi Pharmaceutical Co. Ltd. patent.
Schizophrenia (SCZ) could be associated with genetic alterations that can appear at the beginning of life. Such somatic variants in the NRXN1 and ABCB11 genes could lead to SCZ, according to researchers at Boston Children’s Hospital.
Researchers from Stanford University and affiliated organizations have provided details on the discovery and preclinical evaluation of [11C]MGX-10S, a novel PET tracer for GPR84, which is a G protein-coupled receptor (GPCR) expressed predominately on myeloid cells.
With the approval of Aduhelm (aducanumab, Eli Lilly & Co.) and Leqembi (lecanemab, Eisai Co. Ltd.), there are finally amyloid-targeting drugs available for Alzheimer’s disease (AD). What’s not available, though, are rose-colored glasses of the prescription strength that would make these approvals look like AD’s happy ending. The biopharma industry is already well aware of the need for broader horizons. Roughly three-quarters of drugs now in clinical development for AD target neither amyloid-β (Aβ) nor tau. Still, the genetic evidence from familial AD strongly implicates Aβ processing in AD’s origins. In his opening plenary talk at the European Academy of Neurology 2023 annual conference, Thomas Südhof suggested new ways to look at the clinical data.
Prothena Biosciences Ltd. has developed dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors reported to be useful for the treatment of Alzheimer’s disease.
RSS
